# Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase

> **NCT04160468** · PHASE3 · TERMINATED · sponsor: **ContraFect** · enrollment: 259 (actual)

## Conditions studied

- Staphylococcus Aureus Bacteremia
- Staphylococcus Aureus Endocarditis

## Interventions

- **DRUG:** Exebacase
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04160468
- **Lead sponsor:** ContraFect
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-20
- **Primary completion:** 2022-09-09
- **Final completion:** 2022-09-09
- **Target enrollment:** 259 (ACTUAL)
- **Why stopped:** The independent DSMB recommended that the study be stopped for futility following interim efficacy analysis.
- **Last updated:** 2023-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04160468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04160468, "Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04160468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*